Brief: Newamsterdam Pharma To Announce Topline Data From Pivotal Phase 3 Brooklyn Clinical Trial On Monday
26/07/2024 23:32
July 26 (Reuters) - NewAmsterdam Pharma Company NV
KH6.F :
* NEWAMSTERDAM PHARMA TO ANNOUNCE TOPLINE DATA FROM PIVOTAL
PHASE
3 BROOKLYN CLINICAL TRIAL EVALUATING OBICETRAPIB IN PATIENTS
WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ON MONDAY, JULY
29, 2024
* NEWAMSTERDAM PHARMA COMPANY NV - TO REPORT PHASE 3
BROOKLYN
TRIAL DATA ON JULY 29
Source text for Eikon: ID:nGNX34Gg7F
Further company coverage: KH6.F
((reuters.briefs@thomsonreuters.com;))
Recent news on NewAmsterdam Pharma
See all newsBrief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)